Biotechnology company BioMimetix JV LLC announced on Thursday the publication of results from a multicentre Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC).
The single-arm Phase I/II study enrolled 29 patients with stage III–IV head and neck squamous cell carcinoma who received the investigational drug, BMX-001, in combination with chemoradiation therapy. It found that BMX-001 was safe and well tolerated and suggested substantial efficacy in mitigating treatment-related toxicities, including oral mucositis, xerostomia, and radiation dermatitis, in patients who received standard of care chemoradiation.
The results have been published in the International Journal of Radiation Oncology, Biology, Physics.
BMX-001 is a redox-active superoxide dismutase mimic that down-regulates oxidative stress pathways associated with radiation therapy, while stimulating repair pathways. These same impacts of BMX-001 inhibit tumour cell growth because of the unique metabolic pathways active in tumours. Preclinical studies show that BMX-001 protects normal tissues from radiation-induced injury while enhancing tumour responses to treatment.
Ichnos Glenmark Innovation submits IND for ISB 2301 to treat solid tumours
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism